The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2021 | BTKi resistance and it’s management
Jennifer Woyach, MD, of The Ohio State University, Columbus, OH, discusses the occurrence of Bruton tyrosine kinase inhibitor (BTKi) resistance, and how this event is clinically managed. BTKi resistance often occurs in the relapse setting due to acquired mutations at the binding site of the drug which, in the case of ibrutinib, is BTKCys481. Dr Woyach talks on the use of pirtobrutinib (LOXO-305), a highly selective reversible non-covalent BTKi, to manage BTKi resistance in those with acquired mutations from previous BTK treatment. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
